Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Search for FDA Guidance Documents

Search for FDA Guidance Documents

                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents Home
          Regulatory Information
          Search for FDA Guidance Documents
          Postmarketing Safety Reporting for Combination ProductsSearch for FDA Guidance Documents GUIDANCE DOCUMENT
	Postmarketing Safety Reporting for Combination Products
					Guidance for Industry and FDA Staff
		
		July 2019


	Download the  Final Guidance Document
	    
      	      		Read the Federal Register Notice 

    Final

	  
	  
	Share
    Post
    Linkedin

    Email
    PrintDocket Number:
		    FDA-2008-N-0424
	    	    		    Issued by:
		    Guidance Issuing Office
          Office of the Commissioner, Office of Clinical Policy and Programs, Office of Combination Products
          Center for Drug Evaluation and Research
          Center for Devices and Radiological Health
          Center for Biologics Evaluation and Research


**This guidance document is being distributed for comment purposes only.**

This guidance addresses how to comply with the final rule on postmarketing safety reporting (PMSR) requirements for combination products that FDA issued on December 20, 2016 (81 FR 92603, hereafter the "combination product PMSR final rule," "final rule," or "rule").  The rule describes how to comply with PMSR requirements for combination products that have received FDA marketing authorization.  Although the PMSR regulations for drugs, devices, and biological products share many similarities, each set of regulations establishes distinct reporting requirements, including reporting triggers and timeframes.  The final rule addresses the application of these regulatory requirements to combination products to ensure consistent and complete reporting while avoiding duplication.

Section II of the guidance provides general information on combination products, how FDA regulates combination products, and a summary of the combination product PMSR final rule.  Section III provides an overview of which entities are subject to the final rule and what safety reporting requirements apply to such entities.  Section IV provides more detailed discussion of specific combination product PMSR report types.  Section V provides guidance on where, how, and when to submit PMSR reports to FDA.  Section VI provides hypothetical scenarios that illustrate how to comply with certain combination product PMSR requirements.  While this guidance focuses on the requirements of the combination product PMSR final rule, it also addresses associated topics including postmarketing safety reporting requirements applicable to entities not covered by the rule (see Appendix 3).

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities.  Instead, guidance documents describe the agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word “should” in agency guidance documents means that something is suggested or recommended, but not required.


 
	Submit Comments
	   		  			    		Submit Comments Online
					You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
						If unable to submit comments online, please mail written comments to:
						Dockets Management
							Food and Drug Administration
							5630 Fishers Lane, Rm 1061
							Rockville, MD 20852
						All written comments should be identified with this document's docket number: FDA-2008-N-0424.

                                                                                  Content current as of:
      07/22/2019
         
                  
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical DevicesTopic(s)
			  Combination ProductsSearch for FDA Guidance Documents

        Search for FDA Guidance Documents

          
                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop